


1 **Supplementary figures**

2

3



4

5 **SI Figure 1: Growth in the different drug concentrations of the gradient.** For

6 each drug, amikacin (AMK), piperacillin (PIP) and tetracycline (TET) OD<sub>600</sub> values

7 for each drug concentration in the 10 dilutions of a two-fold gradient are shown in

8 order to illustrate how we chose our cut-off value to define distinct growth. As it can

9 be seen higher OD<sub>600</sub> values are reached during the course of the experiment but


10 OD<sub>600</sub> values in the beginning are fairly low. In order to be able to use the same cut

11 off value for one drug for the entire experiment we chose the lowest possible OD<sub>600</sub>

12 value that shows distinct growth compared to the background we chose OD<sub>600</sub> > 0.1

13 for AMK and TET and OD<sub>600</sub> > 0.3 for PIP.

14



15

16 **SI Figure 2: Effect of the dilution or inoculum size on the IC<sub>50</sub>.** Freshly growing


17 MG1655 was inoculated into 10 dilutions of a two-fold gradient for three different

18 drugs: amikacin (AMK) with an EUCAST MIC of 2 mg/l, piperacillin (PIP) with an


19 EUCAST MIC of 1-2 mg/l and tetracycline (TET) with an EUCAST MIC of 1 mg/l.

20 From the well with the highest drug concentration that showed growth (as defined in

21 Materials & Methods) new gradients were inoculated in triplicates with 10, 20, 100  
 22 and 1000 fold dilution. The IC<sub>50</sub> values of these gradients were determined and are  
 23 presented in this graph. A 10-fold dilution seems to elevate the IC<sub>50</sub> values for AMK  
 24 and TET, suggesting inoculum effect. Therefore, a 20-fold dilution was chosen for the  
 25 adaptive laboratory evolution experiment.  
 26



27  
 28 **SI Figure 3: OD<sub>600</sub> of increment lineages before daily transfer.** The OD<sub>600</sub> is  
 29 displayed for all increment lineages grouped by experimental setup (25, 50 and 100 %  
 30 increments) and the three drugs they have been adapted to: amikacin (AMK),  
 31 piperacillin (PIP) and tetracycline (TET). In most cases the OD<sub>600</sub> declined before  
 32 extinction of the lineages. The different colors represent the eight different replicates.  
 33




34

35 **SI Figure 4: IC<sub>85</sub> relative to the wild type compared to the doubling time relative**  
 36 **to the wild type.** The three plots are divided by the three drugs amikacin (AMK),  
 37 piperacillin (PIP) and tetracycline (TET). The different colors represent the different  
 38 experimental setups. Strains are plotted according to their relative resistance  
 39 compared to the wild type (WT) and their relative doubling time. The strains marking  
 40 the outer area of all strains belonging to one experimental setup are connected. No  
 41 distinct correlation between high resistance with longer doubling time and low  
 42 resistance with shorter doubling time can be identified.


43

44



45  
46  
47  
48  
49  
50  
51  
52  
53  
54

**SI Figure 5: Meta-analysis of the sequencing data.** (A) Number of different mutation types, discriminating between deletions (DEL), large deletions (L\_DEL), insertions (IN), large insertions (L\_IN) and single nucleotide polymorphisms (SNP). (B) Number of mutations per strain discriminating the lineages in color by the drugs they have been adapted to (amikacin (AMK), piperacillin (PIP) and tetracycline (TET)). According to a t.test no significant ( $P > 0.5$ ) difference can be detected between the experiments.



55  
56  
57  
58  
59  
60  
61

**SI Figure 6: Overlap of mutated genes between the gradient evolved lineages, the clones adapted to 25 % increments and a database.** In total 13 different genes have been found to be mutated in clones evolved in the gradient system and 19 different genes were mutated in lineages adapted with the 25 % increments. 90 genes were found to be mutated in 5 % of sequenced clinical *E. coli* strains. More than half of the mutations found in the gradient (7) and increment 25 % (10) adapted clones

- 62 overlap with the database and all genes (5) that were mutated in both approaches
- 63 overlap with the database.

64 **Table legends**

65

66 **SI Table 1: Plate design and drug concentrations of the gradient adaptive**  
67 **laboratory evolution experiment.**

68

69 [https://www.dropbox.com/s/mmacwahfojkgwzm/Gradient\\_concentrations.xlsx?dl=0](https://www.dropbox.com/s/mmacwahfojkgwzm/Gradient_concentrations.xlsx?dl=0)

70

71 **SI Table 2: OD600 values at each transfer of the gradient adaptive evolution**  
72 **experiment.** This table contains all OD600 values and drug concentrations of the well  
73 that was chosen to inoculate a new gradient during the adaptive laboratory evolution  
74 experiment.

75

76 [https://www.dropbox.com/s/esgdsc2mqyl54vu/OD\\_values\\_at\\_each\\_transfer.xlsx?dl=](https://www.dropbox.com/s/esgdsc2mqyl54vu/OD_values_at_each_transfer.xlsx?dl=0)

77 [0](https://www.dropbox.com/s/esgdsc2mqyl54vu/OD_values_at_each_transfer.xlsx?dl=0)

78

79 **SI Table 3: Drug concentrations of the increment approaches.** This table gives the  
80 drug concentrations of each antibiotic for the adaptive laboratory evolution  
81 experiment for the three increment approaches.

82

83 [https://www.dropbox.com/s/xgvp3rpcyxw23kp/Increment\\_concnetrations.xlsx?dl=0](https://www.dropbox.com/s/xgvp3rpcyxw23kp/Increment_concnetrations.xlsx?dl=0)

84

85 **SI Table 4: Sequencing data analysis.** The table contains information about the  
86 average coverage, quality (phred score) and mapping properties of the sequencing  
87 data for every strain.

88

89 [https://www.dropbox.com/s/y2ifxkq2zok81ez/Sequencing\\_analysis.xlsx?dl=0](https://www.dropbox.com/s/y2ifxkq2zok81ez/Sequencing_analysis.xlsx?dl=0)

90

91 **SI Table 5: List of all mutations identified in the sequenced strains.** Information  
92 about all mutations identified in the sequenced strains, including position of the  
93 mutation, frequency, type of mutation, annotated gene, coverage and a reference  
94 explaining the potential role in antibiotic resistance, is listed in the table.

95

96 [https://www.dropbox.com/s/vxzyioyey9uq48q/Genotypic\\_changes.xls?dl=0](https://www.dropbox.com/s/vxzyioyey9uq48q/Genotypic_changes.xls?dl=0)